肿瘤细胞治疗研究
英文原题：Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.
过去几十年间，乳腺癌的系统治疗取得了显著进展。
过去几十年，乳腺癌全身治疗取得显著进展。免疫检查点抑制剂（ICI）的引入显著改善了实体瘤恶性肿瘤的临床结局。然而，目前ICI在乳腺癌中的适应证仅限于三阴性乳腺癌（TNBC）。在高危管腔B型激素受体阳性（HR+）乳腺癌及HER2阳性乳腺癌中，新辅助治疗阶段ICI联合化疗仅显示有限疗效。为满足尚未满足的临床需求，多种新型免疫治疗策略正在进行中的临床试验中接受评估，本文对此进行了综述，包括双特异性抗体、CAR-T 细胞疗法（CAR-T）、T细胞受体（TCR）疗法、TIL（肿瘤浸润淋巴细胞）疗法、肿瘤疫苗和溶瘤病毒疗法。
The systemic treatment of breast cancer has evolved remarkably over the past decades. With the introduction of immune checkpoint inhibitors (ICIs), clinical outcomes for solid tumor malignancies have significantly improved. However, in breast cancer, the indication for ICIs is currently limited to triple-negative breast cancer (TNBC) only. In high-risk luminal B hormone receptor-positive (HR+) breast cancer (BC) and HER2-positive (HER2+) BC, modest efficacy of ICI and chemotherapy combinations were identified in the neoadjuvant setting. To address the unmet need, several novel immunotherapy strategies are being tested in ongoing clinical trials as summarized in the current review: bispecific antibodies, chimeric antigen receptor T-cell therapy (CAR-T), T-cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs), tumor vaccines, and oncolytic virus therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
